Due to its substantially lower kidney and spleen accumulation, the radioconjugate [225Ac]Ac-mcp-M-alb-PSMA possessing only one PSMA- and albumin-binding unit represents a promising candidate for the treatment of metastatic castration-resistant prostate cancer as well as for further theranostic applications in combination with 133La as diagnostic match. The gene discussed is FOLH1; the disease is prostate cancer.